Literature DB >> 7093105

Intravenous labetalol in the treatment of severe hypertension.

A M Cumming, J J Brown, A F Lever, J I Robertson.   

Abstract

1 We have compared, in patients with severe hypertension, the administration of intravenous labetalol by single rapid injection, by repeated bolus injections, and by incremental infusion. 2 Incremental infusion was the most consistently (albeit not invariably) effective method, and that least prone to cause side-effects. 3 An occasional very marked decrease in blood pressure was seen with all these techniques but least often with incremental infusion. Thus close and continuous supervision is mandatory. 4 All three methods produced slight but significant decreases in heart rate, and in plasma angiotensin II and aldosterone. 5 Intravenous labetalol was also effective in controlling hypertensive crises of phaeochromocytoma and those following the withdrawal of clonidine. 6 In a total of 70 severely hypertensive patients given intravenous labetalol, none showed adverse neurological or cardiological sequelae.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093105      PMCID: PMC1401836          DOI: 10.1111/j.1365-2125.1982.tb01895.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Ischaemic brain damage of cerebral perfusion failure type after treatment of severe hypertension.

Authors:  D I Graham
Journal:  Br Med J       Date:  1975-12-27

2.  Intravenous labetalol in hypertensive emergency.

Authors:  A M Cumming; D L Davies
Journal:  Lancet       Date:  1979-04-28       Impact factor: 79.321

3.  Labetalol in hypertension.

Authors: 
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321

4.  Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.

Authors:  P M Trust; E A Rosei; J J Brown; R Fraser; A F Lever; J J Morton; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

5.  Management of complicated hypertension including hypertensive emergencies.

Authors:  D W Richardson; A J Raper
Journal:  Cardiovasc Clin       Date:  1978

6.  Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.

Authors:  E A Rosei; J J Brown; A F Lever; A S Robertson; J I Robertson; P M Trust
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

7.  Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension.

Authors:  A M Cummings; J J Brown; R Fraser; A F Lever; J J Morton; D A Richards; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

  7 in total
  4 in total

Review 1.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

2.  Labetalol: the nineteen-eighties.

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 3.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 4.  Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

Authors:  P Lund-Johansen
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.